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Part of the inflammatory response in Alzheimer’s
disease (AD) is the upregulation of the inducible nitric
oxide synthase (NOS2) resulting in increasedNOpro-
duction. NO contributes to cell signaling by inducing
posttranslational protein modifications. Under path-
ological conditions there is a shift from the signal
transducing actions to the formation of protein tyro-
sine nitration by secondary products like peroxyni-
trite and nitrogen dioxide. We identified amyloid
b (Ab) as an NO target, which is nitrated at tyrosine
10 (3NTyr10-Ab). Nitration of Ab accelerated its
aggregation and was detected in the core of Ab
plaques of APP/PS1 mice and AD brains. NOS2 defi-
ciency or oral treatmentwith the NOS2 inhibitor L-NIL
strongly decreased 3NTyr10-Ab, overall Ab deposi-
tion and cognitive dysfunction in APP/PS1 mice.
Further, injection of 3NTyr10-Ab into the brain of
young APP/PS1 mice induced b-amyloidosis. This
suggests a disease modifying role for NOS2 in AD
and therefore represents a potential therapeutic
target.
INTRODUCTION
Alzheimer’s disease (AD) is clinically characterized by progres-
sive memory loss and decline of cognitive functions. Besides
the classical histopathological hallmarks, extracellular amyloid
b (Ab) deposition and neurofibrillary tangles of tau protein, neuro-
inflammation has been established as a major component
(Querfurth and LaFerla, 2010). This inflammatory response
includes the activation of astrocytes andmicroglial cells localized
to senile plaques and the release of biochemical markers,
including cytokines, chemokines, and nitric oxide, that are found
to be increased in the brains of patients with AD (Glass et al.,2010). While the generation of Ab peptides from the amyloid
precursor protein as well as their propensity to aggregate into
b-cross sheet fibrils has been well characterized (Querfurth
andLaFerla, 2010), themutual interactions betweenneuroinflam-
mation, Ab formation and deposition remain to be elucidated.
While neuronal nitric oxide synthase 1 (NOS1) is constitutively
expressed in a subset of neurons, AD-associated inflammation
can increase NOS1 and the inducible nitric oxide synthase
(NOS2) expression in neurons (Ferna´ndez-Vizarra et al., 2004;
Vodovotz et al., 1996; Heneka et al., 2001) along with the upre-
gulation of NOS2 in microglia and astrocytes (Ferna´ndez-Vizarra
et al., 2004; Vodovotz et al., 1996; Heneka et al., 2001). NOS2
catalyzes the generation of NO, which has been implicated in
impairment of mitochondrial respiration (Beal, 2000), synaptic
failure, and neuronal cell death (Nakamura and Lipton, 2009)
during neurodegeneration. One of the fingerprints of NO is tyro-
sine nitration, a posttranslational protein modification, resulting
in the formation of 30-nitrotyrosine residues (Radi, 2004) that
can induce structural changes leading to protein aggregation
(Radi, 2004). Indeed, AD lesions reveal the pathological pattern
of nitrosative injury (Ferna´ndez-Vizarra et al., 2004; Castegna
et al., 2003; Colton et al., 2008; Lu¨th et al., 2002), prominently
in brain areas that are affected in AD (Hensley et al., 1998).
So far, it is unknown why the Ab peptide, present at high levels
under nonpathological conditions in humans, under certain
circumstances starts to multimerize leading to the formation of
Ab oligomers and further to high molecular weight fibrils and
plaques. In murine models of AD, the overexpression of the
human amyloid precursor protein (APP) results in the formation
of plaque pathology, whereas wild-type mice and rats do not
innately develop amyloid deposits with age (Shivers et al.,
1988), even after overexpression of endogenous APP (Jankow-
sky et al., 2007).
APP is a highly conserved transmembrane protein with only
4% difference in amino acid between human, monkey, mouse,
and rat sequence. Three of these differences (R5/ G, Y10/
F, and H13 / R) are localized to the Ab domain (Figure 1A),
giving rise to speculations about the importance of these




Figure 1. Detection of Ab Nitrated at Tyrosine 10 in AD Brains
(A) Amino acid alignment of human, mouse/rat Ab. Differences are colored.
(B) 3NTyr10-Ab antiserum specifically detects nitrated Ab. Ab1-42 (Ab42) and
the Ab1-42Y10F mutant (Ab42Y10F) were incubated in the absence and
presence of peroxynitrite and immunoblotted using 3NTyr10-Ab antiserum. In
addition, synthetically nitrated Ab1-42 (Ab42(3NT)Y) was used as a control.
Samples were reprobed using antibody 6E10.
(C) Immunohistochemical detection of nitrated Ab in human AD tissue using
IC16 against Ab and 3NTyr10-Ab antiserum by confocal microscopy. Nitrated
Ab was detected in the core of amyloid plaques (bar = 20 mm).
D) Relative quantification of Ab1-38, 1-40, 1-42 and 3NTyr
10-Ab in the SDS
fraction of AD brains and controls measured by sandwich ELISA (n = 5 for
control and n = 8 for AD ± SEM, Student-s t test, *p < 0.05, ***p < 0.001).
See also Figure S1.
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Nitration of Amyloid b in Alzheimer’s Diseasecontaining thesemutations do not differ in the propensity to form
high molecular weight aggregates in vitro (Wahle et al., 2006). An
alternative explanation could be that posttranslational modifica-
tions of the Ab peptide are essential to initiate its aggregation, as
it has been shown for pyroglutamate-modified Ab (Querfurth and
LaFerla, 2010; He and Barrow, 1999). Of note, induction of
aggregation by NO modifications has been reported for other
disease-relevant proteins (Nakamura and Lipton, 2009). With re-
gards to the amino acid sequence of Ab, the tyrosine at position
10 is a potential target for protein nitration.
Since there is so far no mechanistic explanation of how
expression of NOS2 and the subsequent production of NO834 Neuron 71, 833–844, September 8, 2011 ª2011 Elsevier Inc.and its reaction products modulate the progression of AD,
we speculated that nitration of Ab might contribute to AD
pathology.
We report here the presence of Ab nitrated at tyrosine 10 in
AD as well as in AD mouse models. This modification acceler-
ated the deposition of human Ab. We further find that Ab
burden and deficits in memory formation were ameliorated in
APP/PS1 NOS2 (/) mice or by pharmacological treatment
with a NOS2 inhibitor. Finally, nitrated Ab was able to induce
b-amyloidosis in APP/PS1 mice. These results underline the
importance of this posttranslational modification as a potential
therapeutic target.
RESULTS
Detection of Nitrated Ab in AD Tissue
Since tyrosine 10 represents a potential nitration side (Fig-
ure 1A), we tested the availability of this amino acid for this
posttranslational modification in vitro. Performing mass spec-
trometry analysis after tryptic digestion of Ab1-42 that was either
nitrated using peroxynitrite or the NO-donor Sin-1, we observed
the described fragmentation pattern of a nitrated peptide
(Petersson et al., 2001). This pattern was missing using Ab1-42
bearing a tyrosine to alanine mutation (see Figure S1 available
online), suggesting that tyrosine 10 is a potential nitration target
in vitro.
To detect Ab nitrated at tyrosine 10 (3NTyr10-Ab), we
generated an antiserum specifically recognizing this epitope
(3NTyr10-Ab antiserum). This antiserum showed strong immu-
noreactivity against peroxynitrite-treated Ab1-42 peptide or
synthetically-nitrated Ab1-42 (Ab42(3NT)Y), which was absent
in case of the untreated peptide (Figure 1B). We observed a
very low amount of reactivity when treating Ab1-42Y10F mutant
peptide with peroxynitrite. This might be caused by the con-
version of phenylalanine to tyrosine by hydroxyl radicals gen-
erated during the decomposition of peroxynitrite (Ferger
et al., 2001). In accordance with this, there was no reactivity
toward Ab1-42 bearing a Y10A mutation after incubation with
peroxynitrite (Figure S1). Using this antiserum, we were able
to detect 3NTyr10-Ab in the supernatant of NOS2 overex-
pressing HEK293 cells after exogenous addition of non-
aggregated Ab, demonstrating that NOS2 is able to induce
this posttranslational modification before Ab deposits form
(Figure S1).
Immunohistochemical analysis of AD and control brains
by 3NTyr10-Ab antiserum revealed a lack of immunoreactivity
in control brains, whereas in AD brain, the core of amyloid pla-
queswas intensively labeled, as confirmed by IC16 double stain-
ing (Figure 1C). Measuring the relative amounts of 3NTyr10-Ab by
sandwich ELISA in SDS-soluble fractions of human brain
samples, we detected 3NTyr10-Ab in the SDS fraction of AD
patients and only to very low amount in nondemented controls
(Figure 1D). Further, the relative signal ratio of 3NTyr10-Ab
between control and AD patients was comparable to that of
Ab1-42 (Figure 1D). Of note, we failed to detect any 3NTyr
10-Ab
in human cerebrospinal fluid (CSF) of control, mild cognitive
impaired, and AD patients underlining the insoluble properties









Figure 2. Nitrated Ab Is Present in APP/PS1 Mice and Is Reduced
after NOS2 Knockout
(A) Nitrated Ab is already detectable in the cortex of 5-month-old APP/PS1
transgenic mice using antibody IC16 (Ab) and 3NTyr10-Ab antiserum (bar =
50 mm).
(B) Detection of nitrated Ab in 12-month-old APP/PS1 mice using antibody
IC16 (Ab) and 3NTyr10-Ab antiserum (bar = 50 mm).
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Analysis of brain sections from 5- and 12-month-old APP/PS1
mice revealed a colocalization of antibody IC16 against Ab
with the 3NTyr10-Ab antiserum from beginning of plaque forma-
tion starting at 5 months of age in this AD mouse model (Figures
2A and 2B). This costainingwas observed in all brain areaswhere
amyloid plaques are formed. In addition, colocalization was
observed independently of plaque size, since it was already
detectable in tiny plaques of 10 mm diameter in 5-month-old
animals (Figure 2C), suggesting that formation of 3NTyr10-Ab is
an early event in plaque development. Similar to human AD
brain, in APP/PS1 the 3NTyr10-Ab immunoreactivity was local-
ized to the core of the plaque surrounded by IC16 immunoreac-
tivity (Figure 2D).
Evaluation of individual Ab plaque sizes by immunohistochem-
istry with antibody IC16 and the area of the 3NTyr10-Ab positive
core of 5- and 9-month-old APP/PS1 mice revealed that there
are no changes in the average 3NTyr10-Ab core size (Figures
2E and 2F), suggesting that the core, once formed, does not
substantially increase in size any further. Nevertheless, we
observed plaque growth between 5 and 9 months that was
solely caused by accumulation of nonnitrated Ab, as detected
by IC16 immunoreactivity (Figures 2E and 2F). As a conse-
quence, there was a highly significant drop in the 3NTyr10-Ab/Ab
ratio (Figure 2G).
In addition, we were able to immunoprecipitate 3NTyr10-Ab
of brain homogenates sequentially extracted with PBS, RIPA,
SDS, and HIFP using 3NTyr10-Ab antiserum. Using 6E10 as
detection antibody, we were able to detect high amounts of
nitrated Ab in the SDS-soluble fraction and to smaller extent in
the RIPA- and HFIP-soluble fractions of APP/PS1 mice (Fig-
ure 2H). Determining the relative amounts of 3NTyr10-Ab in
SDS fractions of wild-type, APP/PS1, and APP/PS-1 NOS2
(/) animals by sandwich ELISA, we were unable to detect
this species in wild-type mice, but in APP/PS1 mice. In turn,
APP/PS1 mice lacking NOS2 (/) showed a 74% reduction
of 3NTyr10-Ab (Figure 2I).(C) Nitrated Ab are detectable in small plaques of around 10 mm in diameter
(bar = 10 mm).
(D) Confocal 3D reconstruction of an Ab plaque from a APP/PS1 mouse using
IC16 and 3NTyr10-Ab (bar = 20 mm).
(E) Section from 5- and 9-month-old APP/PS1 mice were probed for 3NTyr10-
Ab and Ab using antibody IC16. Individual plaques were analyzed for 3NTyr10-
Ab and Ab area. (n = 4 mice, 275 plaques per group; lines, linear regression
analysis; dashed lines, 95% confidence intervals, R2 = 0.51 for 9 month group
and R2 = 0.57 for 5 month group).
(F) Statistical analysis of the average 3NTyr10-Ab and Ab areas revealed that
plaque growth increases Ab area, whereas 3NTyr10-Ab area remains constant
(mean ± SEM of n = 4 mice, 275 plaques per group analyzed, Student’s t test).
(G) 3NTyr10-Ab/Ab area ratios of individual plaques (mean ± SD of n = 4 mice,
275 plaques per group analyzed, Student’s t test, ***p < 0.001).
(H) Brains of 12-month-old wild-type and APP/PS1 mice were sequentially
extracted with PBS, RIPA, SDS, and finally with HFIP. Fractions were immu-
noprecipitated using 3NTyr10-Ab antiserum and immunoblotted using anti-
body 6E10. In addition, fractions were immunoblotted for Ab and APP using
antibodies 6E10 and CT15.
(I) 3NTyr10-Abwasmeasured by sandwich ELISA in SDS fractions of wild-type,
APP/PS1, and APP/PS1 NOS2 (/) mice at 12 months of age (n = 4 ± SEM,
Student’s t test, **p < 0,01).





Figure 3. Nitration of Ab at Tyrosine 10
Induces Its Aggregation
(A) Aggregation of synthetic Ab1-42 (Ab42), nitrated
Ab1-42 (Ab42+PN), and nitrated Ab1-42Y10F
(Ab42Y10F + PN) was analyzed by western blot
using antibody 6E10 (HMW oligomers, high
molecular weight oligomers).
(B) Reprobingwith 3NTyr10-Ab antiserum to detect
Ab nitration.
(C) Graphical evaluation of three independent
experiments normalized to Ab monomer (n = 3 ±
SEM, two-way ANOVA, Bonferroni post test,
***p < 0.001).
(D) ThioflavinTaggregationassayofsyntheticAb1-42
(Ab42), nitrated Ab1-42 (Ab42+PN), and nitrated
Ab1-42Y10F (n = 3 ± SEM, two-way ANOVA Ab42
versus Ab42 + PN, Bonferroni post test, *p < 0.05).
(E) Dot blot analysis of Ab1-42 (25 mM) after treat-
ment with increasing concentration of peroxyni-
trite using antibody IC3 against dityrosine (DT),
IC16 (Ab), and 3NTyr10-Ab antiserum.
(F) Dot blot analysis of Ab1-42 (25 mM) for dityrosine
(DT) after treatment with 250 mM of peroxynitrite,
aggregation for 5 hr and subsequent centrifuga-
tion at 10000xg for 1 hr (S, supernatant; P, pellet).
(G) Confocal 3D reconstruction of an Ab plaque
from a 9-month-old APP/PS1 mouse using anti-
bodies IC3 (dityrosine) and IC16 (Ab) (bar = 20 mm)
and using antibody IC3 (dityrosine) and 3NTyr10-
Ab antiserum (bar = 20 mm).
See also Figure S2.
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Since N-terminal modifications of Ab have been shown to induce
its aggregation, we speculated whether nitration of Ab exerts
a similar effect. Indeed, incubation of synthetic Ab1-42 with per-
oxynitrite or the NO donor Sin-1 resulted in increased generation
of high molecular weight SDS-resistant oligomers (Figures 3A
and S2). Using Ab1-42 peptides with a tyrosine to alanine or
phenylalanine mutation (Ab42Y10A or Ab42Y10F) reduced
aggregation to the level of untreated Ab1-42 (Figures 3A and836 Neuron 71, 833–844, September 8, 2011 ª2011 Elsevier Inc.S2). In case of the nonmutated Ab1-42,
we observed the incorporation of nitrated
Ab1-42 into oligomers (Figure 3C). There
was a very low amount of nitrated
Ab1-42Y10F detectable using the 3NTyr
10-
Ab antiserum. Finally, we confirmed our
western blot results by detecting an
increased formation rate of b sheet
amyloid fibril structures of nitrated Ab1-42
using thioflavin T (Figure 3D), which was
prevented using the Ab42Y10F peptide
treated with peroxynitrite.
Oxidative conditions can also result in
the formation of dityrosine cross-linked
proteins (Kato et al., 2000). We therefore
investigated whether peroxynitrite is able
to induce this modification as well. Using
the dityrosine specific antibody IC3 we
were able to detect dityrosine cross-linked Ab in vitro after incubation with increasing concentrations
of peroxynitrite (Figure 3E). High concentrations of peroxynitrite
resulted in decreased formation of this species, whereas
formation of 3NTyr10-Ab increased even further (Figure 3E).
Dityrosine immunoreactivity was also found to be present in
the insoluble fractions of aggregated Ab (Figure 3F). In addition,
we performed immunohistochemical analysis of dityrosine
with Ab or 3NTyr10-Ab in sections of APP/PS1 mice, revealing
plaque localization and 3NTyr10-Ab colocalization of dityrosine
Neuron
Nitration of Amyloid b in Alzheimer’s Diseaseimmunoreactivity (Figure 3G). These results suggest that dityro-
sine formation might also contribute to Ab aggregation.
NOS2 Deficiency Protects from Behavioral Phenotype
and Reduces Ab Load in APP/PS1 Mice
Looking at effects on spatial memory formation by radial arm
maze in 12-month-old APP/PS1 mice, we noticed a strong
protection of the NOS2 gene knockout for memory deficits (Fig-
ure 4A). In addition, we conducted a therapeutic approach by
treating plaque containing mice from 7–12 months with the
selective NOS2 inhibitor L-NIL resulting in a reversion of APP/
PS1 phenotype concerning referencememory errors (Figure 4A).
Since memory formation and synaptic plasticity are closely
connected, we determined the hippocampal long-term potentia-
tion (LTP) of the CA1 region in response to a stimulus of the
Schaffer’s collaterals in WT, APP/PS1, NOS2 (/), APP/PS1
NOS2 (/), and APP/PS1 L-NIL treated mice at 4 months (Fig-
ure S3). APP/PS1 mice of that age already contain insoluble,
high-density amyloid depositions that are positive 3NTyr10-Ab
(Figure S3), that were also found at later age, as well as in AD
patients (Figure S3). Analysis of the LTP in APP/PS1 mice
showed a reduction LTP, which was not observed in wild-type,
NOS2-deficient, or L-NIL-treated mice (Figure S3).
In order to establish a causal link between the observed
protective phenotype of NOS2 deficiency and Ab nitration, we
studied the effects of nitrated Ab on synaptic plasticity. There-
fore we treated wild-type (WT) mice acute hippocampal slices
with either untreated Ab1-42, nitrated Ab1-42, or a control sample
that underwent the same nitration steps without adding Ab. The
application of untreated Ab1-42 decreased LTP 55–60 min after
TBS application compared to the slices treated with the control
sample (p = 0.03, Student’s t test); Figure 4B). When Ab1-42 was
additionally nitrated, the initial phase of LTP was already signifi-
cantly decreased compared to controls and this resulted in
highly significant differences 55–60 min after TBS (p = 0.0001,
Student’s t test). The average potentiation in control treated sli-
ces was 199 ± 8.6% (n = 11 slices /5 animals), Ab1-42 treated sli-
ces reached a value of 163% ± 10.9% (n = 11 slices/6 animals),
and peroxynitrite treated Ab1-42 led to a potentiation of 141% ±
7.8% (n = 12 slices/7 animals) (Figure 4B). Comparing the results
of the nitrated Ab1-42 with the untreated Ab1-42 revealed that the
nitrated Ab1-42 showed a significantly reduced potentiation
(t = 60 min, p = 0.02; t = 80 min, p = 0.028; Student’s t test) in
comparison to untreated Ab1-42. Overall the strongest effect on
synaptic plasticity was observed, when Ab1-42 was nitrated.
This is in line with the behavioral data and supports the notion,
that nitrated Ab1-42 is more powerful in disturbing processes of
synaptic plasticity than Ab1-42 alone.
Subsequent analysis of the mice from the behavioral experi-
ment for Ab1-40 and Ab1-42 revealed a strong reduction in the
SDS-soluble fraction (Figures 4C–4F), which was smaller than
the reduction of 3NTyr10-Ab (Figure 2I). Consequently, we
observed an increase in the Ab40/3NTyr10-Ab and Ab42/
3NTyr10-Ab ratio (Figure 4G). There were no changes in the
expression of APP, neprilysin, and IDE at 12 months of age
(Figures 4C and 4D). These findings were confirmed by reduced
plaque load in the neocortex and hippocampus in APP/PS1
NOS2 (/) mice by thioflavin S staining (Figures 4H and 4I). Inkeeping with this, loss of NOS2 activity during the phase of
plaque formation has a beneficial effect on the formation of Ab
deposits.
Nitrated Ab Induces Aggregation and Plaque Formation
It is conceivable that the formation of amyloid plaques needs
a nucleation event. We therefore tested whether nitrated Ab1-42
can act as a seed of deposition. Testing whether small amounts
of nitrated Ab1-42 induces the formation of Ab oligomers in vitro,
we observed a concentration dependent increase in high molec-
ular weight oligomers by western blot analysis (Figure 5A). To
test the hypothesis in vivo, we injected 2.5 ml of a 0.5 mg/ml solu-
tion of either Ab1-42 or nitrated Ab1-42 aged for 18 hr into the brain
of 2.5-month-old APP/PS1 mice. Verification of the injected Ab
peptides by western blot demonstrated the nitration status using
the 3NTyr10-Ab antibody and increased formation of Ab oligo-
mers using antibody 6E10 (Figure 5B). Analysis of the mice after
8 weeks showed strong 3NTyr10-Ab immunoreactivity in case of
the mice injected with nitrated Ab1-42 (Figure 5D). In addition,
nitrated Ab1-42 was able to induce amyloid seeds that were local-
ized distant from the injection side (Figure 5D), that were missing
in mice injected with nonnitrated Ab (Figure 5C). These seeds
were composed of nitrated Ab surrounded by nonnitrated Ab
(Figure 5E), thus resembling the immunomorphological appear-
ance of plaques detected in AD brains. In addition, this species
also evoked an increase of Iba1 suggesting a role for microglial
activation.
DISCUSSION
Direct propagation of Ab aggregation by neuroinflammation is
unknown; even so, this may be important for the development
of disease modifying therapies. In this study, we propose
a causative link among the Ab cascade, activation of NOS2,
and the subsequent increase in its reaction product nitric oxide
during AD.
NO is a free radical gas that functions physiologically as
a diffusible neurotransmitter and signaling molecule. Depend-
ing on its concentration it can conduct different actions. At
low concentrations, it competes with oxygen for cytochrome
oxidase, thereby regulating energy metabolism (Poderoso,
2009). Indirect effects are also mediated by regulating cGMP
synthesis and subsequently cGMP-dependent signaling cas-
cades (Poderoso, 2009). However, at high concentration, NOS2-
derived NO results in the formation of reactive peroxynitrite,
which causes irreversible nitration or nitrosylation of specific
amino acid residues, resulting in aberrant protein conformation
and function, e.g., in the inhibition of mitochondrial respiration
(Szabo´ et al., 2007).
Previously, nitrosative stress has been demonstrated in
disease relevant brain areas in AD (Ferna´ndez-Vizarra et al.,
2004; Castegna et al., 2003; Colton et al., 2008; Lu¨th et al.,
2002; Hensley et al., 1998). In line with this, induction of NOS2
expression has been demonstrated in AD (Vodovotz et al.,
1996; Heneka et al., 2001) and in the Tg2576 AD mouse model
(Rodrigo et al., 2004). Since nitric oxide and its reaction products
like peroxynitrite are able to introduce posttranslational modifi-






Figure 4. Behavioral Protection and Reduced Ab Burden in APP/PS1 NOS2 (–/–) Mice
(A) Working memory errors (left panel) and reference memory errors (right panel) of radial arm maze test at 12 months of age (n = 15 ± SEM, ANOVA followed by
Student-Newman-Keuls test, *p < 0.05; **p < 0.01; ***p < 0.001).
(B) Acute hippocampal slices from wild-type mice were treated for 40 min with untreated Ab1-42, nitrated Ab1-42, or a control sample that underwent the same
nitration steps without adding Ab (control). LTP induction was measured along the CA3-CA1 Schaffer-collateral pathway (n = 11–12, mean ± SEM); a TBS was
applied after 40 min of baseline recording.
(C) Western blot analysis of RIPA and SDS brain extracts of 12-month-old mice.
(D) Quantification of APP expression and SDS-soluble Ab from C (n = 4 ± SEM, Student’s t test, ***p < 0.001).
(E) ELISA quantification of RIPA (upper panel) and SDS (lower panel) fraction for Ab1-40 and 1-42 from 12-month-old APP/PS1 and APP/PS1 NOS2 (/) mice
(n = 5 ± SEM, Student’s t test, *p < 0.05).
(F) 12-month-old APP/PS1- and APP/PS1 L-NIL-treated mice (n = 4 ± SEM, Student’s t test, *p < 0.05).
(G) Evaluation of the Ab and 3NTyr10-Ab ELISA data from APP/PS1 and APP/PS1 NOS2 (/) mice (n = 4 ± SEM, Students t test, *p < 0.05, **p < 0.01).
(H) Thioflavin S histochemistry of APP/PS1 and APP/PS1 NOS2 (/) mice (Hc, hippocampus; Cx, neocortex).
(I) Evaluation of 15 consecutive sections per animal (n = 12 ± SEM, Student’s t test, ***p < 0.001).
See also Figure S3.
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Nitration of Amyloid b in Alzheimer’s Diseasespeculated whether the tyrosine at position 10 of Ab might be
a possible target for NOS2-mediated nitration, thereby influ-
encing its amyloidogenic properties.838 Neuron 71, 833–844, September 8, 2011 ª2011 Elsevier Inc.Indeed, we were able to demonstrate that Ab nitrated at
tyrosine 10 has an increased propensity to form high molecular
weight aggregates in vitro. In line with this, we observed
Figure 5. Induction of b-Amyloidosis by 3NTyr10-Ab
(A) 25 mM Ab1-42 were incubated for 5 hr with increasing amounts of either peroxynitrite (Ab42PN) treated or synthetically nitrated Ab1-42 (Ab42(3NT)Y) and
oligomeric forms were detected using antibody IC16.
(B) Determination of the nitration and aggregation status of Ab1-42 used for intracerebral injection by western blot using 3NTyr
10-Ab (left panel) and 6E10
(right panel).
(C) Ab1-42 and (D) nitrated Ab1-42 were intracerebrally injected into APP/PS1 mice. Sections were analyzed 8 weeks later using antibodies IC16, 3NTyr
10-Ab and
Iba1, and by thioflavin S histochemistry. Bar = 200 mM, lower panel bar = 50 mm.
(E) Enlargement of a newly seeded plaque-like structure from (B). Bar = 2 mM.
Neuron
Nitration of Amyloid b in Alzheimer’s Diseasea protective effect on amyloid plaque formation and memory
function by deleting the NOS2 gene from APP/PS1 mice. Our
data are in accordance with a previous report using the
Tg2576 mouse model crossbred with the human PS1 A246E
mutation (Nathan et al., 2005). In addition, we observed similar
effects after oral long-term application of the NOS2-specific
substrate analog inhibitor L-NIL. Besides its selectivity (23-fold
over NOS1 and 49-fold over NOS3) (Moore et al., 1994; Alderton
et al., 2001), the oral bioavailability and its brain penetration have
been demonstrated (Rebello et al., 2002). Of note, the safety of
L-NIL has already been demonstrated in patients suffering
from asthma and in healthy controls (Hansel et al., 2003).Importantly, improved spatial learning and memory in NOS2
(/) or L-NIL-treated APP/PS1 mice may well be causally
linked to the nitration of Ab1-42 as the latter decreased hippo-
campal long-term potentiation more effectively when compared
to nonnitrated Ab1-42, suggesting that nitration of Ab may exert
a direct effect on synaptic transmission even before its deposi-
tion in plaques. This is additionally supported by the observation
that deletion of NOS2 or L-NIL treatment in young APP/PS1mice
results in improved LTP. Nevertheless, additional NO-mediated
effects, likely to be independent of nitrated Ab, that protect
from Ab-induced suppression of LTP have been reported
(Wang et al., 2004). Further, the reduction of Ab in APP/PS1Neuron 71, 833–844, September 8, 2011 ª2011 Elsevier Inc. 839
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Nitration of Amyloid b in Alzheimer’s DiseaseNOS2 (/) mice may lower the production of proinflammatory
cytokines by activated microglia and astrocytes and thereby
protect from LTP suppression (Hauss-Wegrzyniak et al., 2002;
Griffin et al., 2006; Tancredi et al., 1992, 2000).
In contrast, a beneficial role of NOS2 in an AD mouse model
expressing the APP Swedish mutation has been suggested.
Deletion of NOS2 resulted in increased Ab deposition and
improved spatial memory (Wilcock et al., 2008; Colton et al.,
2006, 2008). Even so there has been no mechanistic explanation
for the changes in Ab burden in this study, a main difference to
our study is the usage of an AD mouse model lacking a PS1
transgene, which may account for the opposite effects observed
in this study and in a previous one (Nathan et al., 2005). Colton
et al. argued that the enhanced upregulation of NOS2 is an
overexpression artifact of the PS1 transgene caused by an
inflammatory response within resident immune cells, as evi-
denced in vitro by Lee et al. (2002). However, such an effect
has not been observed in rodent AD models or in patients with
sporadic AD. Nevertheless, an impact of the PS1 DExon 9 trans-
gene on immune cells, like microglia cells, is unlikely, since the
prion promoter driven APP/PS1 mouse model system used in
this study results in the expression of both transgenes (APPsw
and PS1 DExon 9) almost exclusively confined to neurons
(Kretzschmar et al., 1986).
Based on the evidence presented in this study, we propose
that the observed decrease in amyloid burden in NOS2 knockout
or L-NIL-treated APP/PS1 mice is attributed to a new NO-
induced posttranslational Ab modification that critically in-
creases its aggregation and solubility profile. This is supported
by the observation that nitrated Ab is localized to SDS-soluble
fractions in APP/PS1 mice. In addition, nitrated Ab was not
detectable in the CSF nor in RIPA-soluble tissue fraction but in
SDS-soluble fractions of AD brains. In keeping with this, nitrated
Ab was immunohistochemically localized to the core of plaques
of APP/PS1 mice and human AD brains, suggesting that it
serves as a seeding structure. In addition, immunohistometrical
plaque analysis of APP/PS1 mice at 5 and 9 months of age
revealed that the 3NTyr10-Ab positive cores of amyloid plaques
do not grow over this period of time, whereas total plaque size
increased. This suggests that nitration of Ab defines the number
of amyloid plaques, but not their size once formed.
Supporting this assumption, injection of nitrated Ab resulted in
seeding of microplaques within a short period of time. Hence,
this posttranslational Ab modification may explain why injection
of synthetic Ab into ADmouse models fails as a seeding agent in
AD mouse models (Meyer-Luehmann et al., 2006; Eisele et al.,
2009), in contrast to the use of brain homogenates from murine
AD models or human AD brains, both of which supposedly
contain nitrated Ab. Nevertheless, we neither can rule out other
NO-inducedmechanisms including synaptic failure and neuronal
cell death (Nakamura and Lipton, 2009) contributing to the
protective effect of NOS2 deletion.
The observation that expression of murine APP, lacking the
tyrosine within the Ab domain, does not result in Ab deposition
in mice (Jankowsky et al., 2007) but in rodents endogenously
possessing this tyrosine (Inestrosa et al., 2005), suggests a crit-
ical role for this amino acid in b-amyloidosis. Nevertheless, this
has to be confirmed experimentally.840 Neuron 71, 833–844, September 8, 2011 ª2011 Elsevier Inc.It has been known that fibrillar Ab is able to activate microglia
(Meda et al., 1995), resulting in the induction of NOS2 expression
(Combs et al., 2001; Tran et al., 2001; Ishii et al., 2000). This in
turn may generate a self-perpetuating cycle of Ab aggregation
and NO production that contributes to the chronicity and
progression of AD.
One might argue that the nitration yields under inflammatory
conditions are relatively low, resulting in the modification of
only 0.01%–0.05% of all tyrosine residues (Radi, 2004). How-
ever, in a gain-of-function scenario, nitrated Ab may focally
accumulate over a life time, thereby facilitating the rate-limiting
nucleation step for the initiation of plaque deposition. In support
of this, an 8-fold increase of nitrated proteins has been observed
in AD (Smith et al., 1997). Further, assessing the overall amount
of nitrated proteins in the hippocampus of MCI patients, an
equivalent to the nitration of purified BSA achieved with 27 mM
peroxynitrite was estimated (Butterfield et al., 2007), exposing
the drastic consequences from chronic exposure to nitric oxide
radicals.
Nitration induced oligomerization has also been reported for
other disease-related proteins. Recently, the effects of peroxyni-
trite on oligomerization of a-synuclein by formation of covalent
dityrosine cross-links has been demonstrated (Souza et al.,
2000). In addition, a widespread accumulation of nitrated a-syn-
uclein has found in several neurodegenerative diseases associ-
ated with Lewy bodies (Giasson et al., 2000). Furthermore, the
presence of nitrated tau in AD brains and its peroxynitrite-
induced oligomerization has been observed (Horiguchi et al.,
2003).
Together, our data identify a posttranslational modification of
Ab and characterize its functional implication that provides
evidence for a link between the amyloid and neuroinflammatory
component of AD. We think that 3NTyr10-Abmay be a promising
target for a course modifying therapy of AD. The application of
specific inhibitors of NOS2 may therefore open a new thera-
peutic avenue in AD.
EXPERIMENTAL PROCEDURES
Animals
APP/PS1 transgenic animals (#005864, The Jackson Laboratory) (Jankowsky
et al., 2001) and NOS2-deficient animals (# 002609, The Jackson Laboratory)
(Laubach et al., 1995) were both of the BC57/Bl6 genetic background.
L-NIL was given orally in the water either from 2–3-months or 7–12 months
of age (8 mg/kg body weight). L-NIL was replaced daily. Mice were
housed under standard conditions at 22C and a 12 hr light-dark cycle with
free access to food and water. Animal care and handling was performed
according to the declaration of Helsinki and approved by the local ethical
committees.
Radial Arm Maze
Learning and memory testing was conducted in an eight arm maze as previ-
ously described (Olton, 1987). Briefly, each arm of the maze was 60 cm long
and 6 cm wide and extended from an octagonal central platform 10 cm in
diameter. One centimeter deep food cups were placed 2 cm from the end of
each arm. Several visual cues were put outside of the maze, and the room
was lit dimly. Mice were trained for 3 days. During each training session, the
mouse was placed on the center platform and allowed to move freely in the
maze to obtain food pellets, which were presented in all eight arms, for
10 min. Starting day 4, the mice were tested once per day for a total of
14 days. During the test sessions, four randomly selected arms were baited
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the experiment. The mouse was allowed to move until it collected the four
pellets or until 10 min passed, whichever occurred first. Parameters evaluated
were reentry into baited arms that had been visited during the session (working
memory error) and entries into unbaited arms (reference memory error).The
task was considered learned when the working memory error was zero and
the average reference memory error was one or less than one in three succes-
sive sessions.
Brain Protein Extraction
Snap-frozen brain hemispheres were extracted as previously described
(Jardanhazi-Kurutz et al., 2010).
Tissue Preparation
After completion of the behavioral testing, mice were anesthetized using
isoflurane and transcardially perfused with 15 ml phosphate-buffered saline.
The brains were removed from the skull. One hemisphere was frozen immedi-
ately for biochemical analysis and the other was frozen in a mixture of dry ice
and isopentane for histology.
Protein Blotting
Samples were separated by 4%–12% NuPAGE (Invitrogen) using MES or
MOPS buffer and transferred to nitrocellulose membranes. APP and Ab
were detected using antibody 6E10 (Covance) and the C-terminal APP anti-
body 140 (CT15) (Wahle et al., 2006), IDE using antibody PC730 (Calbiochem),
neprilysin using antibody 56C6 (Santa Cruz), presenilin using antibody PS1-NT
(Calbiochem), and tubulin using antibody E7 (Developmental Studies
Hybridoma Bank). For dot blot analysis, 10 ml samples containing 25 mM
peptide were mixed with 200 ml PBS and transferred to nitrocellulose
membranes. Immunoreactivity was detected by enhanced chemilumines-
cence reaction (Millipore; luminescence intensities were analyzed using
Chemidoc XRS documentation system [Bio-Rad]).
ELISA
Quantitative determination of Ab was performed using the human amyloid
Ab1-40 and Ab1-42 ELISA kits (The Genetics Company) according to the manu-
facturer’s protocol. Human samples were analyzed using an electrochemolu-
minescence ELISA for Ab1-38, Ab1-40, and Ab1-42 (Mesoscale). pTau181 was
determined using the INNOTEST PHOSPHO-TAU(181P) ELISA (Innogenetics).
For 3NTyr10-Ab, 96-well plates were coated with 50 ml 20 mg/ml 3NTyr10-Ab
antiserum in PBS 4 hr at 20C. Plates were blocked with 3% BSA in TBS.
Ten microliters of 2% SDS fractions from mouse brain were diluted with
50 ml 2% Tx-100, 25 mM Tris-HCl (pH 7.5), and 150 mM NaCl. Fifty microliters
samples were incubated for 18 hr at 4C, washed with TBST, and incubated
with 6E10 diluted 1:10,000 in TBST for 2 hr. Wells were washed, and 50 ml
HRP-goat anti-mouse antibody diluted 1:10,000 with TBST was added for
2 hr. After washing, 50 ml TMB ultra substrate (Thermo) was added and the
reaction was stopped using 2M sulfuric acid. Absorption was determined at
450 nm using an infinite 200 plate reader (Tecan).
Histology
Serial sagittal cryosections (20 mm) were fixed in 4% paraformaldehyde, and
immunostaining was performed using antiserum 3NTyr10-Ab (1:200), antibody
IC16 (Ja¨ger et al., 2009) against human Ab1-15 (1:400), rabbit polyclonal anti-
serum 2964 against fibrillar Ab1-42 (Wahle et al., 2006), and antibody IC3 (Kato
et al., 2000) against dityrosine (1:100). Thioflavin S staining was performed on
paraformaldehyde-fixed cryosections. Slices were rinsed in water, incubated
in 0.01% thioflavin S in 50% ethanol, and differentiated in 50% ethanol.
Sections were analyzed using a BX61 microscope equipped with a disk
scanning unit to achieve confocality (Olympus). Image stacks were deconvo-
luted using Cell^P (Olympus). Quantitative assessment of plaque areas was
done using ImageJ (NIH; Bethesda, MD) software.
Immunoprecipitation
Brains were extracted as described before with the following changes:
homogenates were centrifuged at 100,000 3 g for 20 min to generate the
PBS fraction. The pellet of the SDS fraction was extracted with 1,1,1-6,6,6-hexafluoroisopropanol (HFIP), dried in a speed vac and resuspended in 2%
SDS. For immunoprecipitation, samples were diluted in 5 vol. of RIPA buffer
and incubated for 18 hr at 4C with protein G agarose and 3 ml 3-NTyr10-Ab.
Precipitates were washed twice with RIPA and once with PBS and immuno-
blotted using antibody 6E10.
Ab Aggregation Assay
Ab1-42, Ab1-42 Y10F (Peptide Specialty Laboratories) were solubilized as previ-
ously described (Teplow, 2006). For nitration, samples were incubated with
0.25–0.5 mM peroxynitrite in water while vortexing. Aggregation was started
by diluting samples to 25 mM using 50 mM Tris-HCl (pH 7). Samples were
separated by 4%–12% NuPAGE, and aggregates were detected using anti-
body 6E10 (Signet) and 3-NTyr10-Ab. Aggregation was expressed as a ratio
between the signal above 30 kDa and the Ab monomer, normalized to the
0 time point of Ab1-42. Thioflavin T fluorescence assays were performed
as described previously (LeVine, 1999). Fluorescence was read at 446 nm
(excitation) and 482 nm (emission) using a fluorescence spectrophotometer
(Varian). For determination of the solubility of dityrosine linked Ab, samples
were aged for 5 hr and centrifuged at 10, 000 3 g for 1 hr. Pellets were resus-
pended in 50 mM Tris (pH 7) and analyzed by dot blot.
30-Nitrotyrosine-Specific Amyloid b Antiserum
The antiserum recognizing the 3-NTyr10-Ab was generated by rabbit immuni-
zation using the synthetically nitrated peptide FRHDSG(3NT-Y)EVHHQ (Euro-
gentech). The resulting serum was first immunopurified against the nitrated
peptide and subsequently antibodies against the unmodified peptide were
removed by immunochromatography against the peptide FRHDSGYEVHHQ.
Human Samples
Human brain sampleswere from the parietal cortex of 5 age control and 8 diag-
nosed AD patients (Braak staging V–VI, CERAD B–C). The post mortem
interval (PMI) was comparable among groups ranging from 4–48 hr. Samples
were extracted as the mouse brains described above with the exception that
instead of RIPA buffer 25 mM Tris-HCl (pH 7.5), 150mMNaCl, 1% Tx-100 was
used. CSF samples were from 10 control, 10 mild cognitive impaired, and 10
diagnosed AD patients.
Intracerebral Injections
Two and one-half-month-old APP/PS1 mice (n = 3) were anesthetized with
ketamine (30 mg/kg) and xylazine (4 mg/kg). Two and one-half microliters
of 0.25 mg/ml Ab solutions were injected intracortically into the right hemi-
sphere anteroposterior –2.5, lateral 2.0 at 1.0 mm (cortex), and in addition at
1.5 mm (hippocampus) depth relative to the bregma at a rate of 1 ml/min.
Control solutions were injected into the left hemisphere, accordingly. Mice
were sacrificed 8 weeks later. Cryosections in the proximity of the injection
channel were stained using antibodies IC16, 3NTyr10-Ab, and anti-Iba1
(1:400, Wako).
Slice Preparation
Acute hippocampal transversal slices were prepared from 40- to 60-day-old
wild-type C57BL/6 mice (P40–60) according to standard procedures. In brief,
mice were anesthetized and decapitated, the brain was quickly transferred
into ice-cold carbogenated (95% O2, 5% CO2) artificial cerebrospinal fluid
(ACSF) which contained 125.0 mM NaCl, 2.0 mM KCl, 1.25 mM NaH2PO4,
2.0 mM MgCl2, 26.0 mM NaHCO3, 2.0 mM CaCl2, 25.0 mM glucose. Hippo-
campi were dissected and cut into 400 mm thick transversal slices with a vibra-
tome (Leica, VT1200S). Slices weremaintained in carbogenated ACSF at room
temperature for at least 1.5 hr before recording. Recordings were performed in
a submerged recording chamber at 32C.
Electrophysiology
To study the effect of acute Ab application on LTP three different samples were
used: (1) untreated Ab1-42, (2) nitrated Ab1-42 with peroxynitrite (500 mM), (3)
a control sample where all nitration steps were performed without adding
Ab1-42 (control). Ab1-42 was prepared as previously described (Teplow,
2006). Nitration was carried out by adding water diluted peroxynitrite to
Ab1-42 or control sample solution while vortexing. The solutions were freshlyNeuron 71, 833–844, September 8, 2011 ª2011 Elsevier Inc. 841
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500 nM. Silicon tubing was used and BSA (0.1 mg/ml) was added to the
peptide containing as well as to the control solutions (Chen et al., 1999).
Tubings and beakers were washed with ACSF containing BSA to prevent
sticking of the peptide. A closed-loop perfusion system with a total volume
of 30 ml perfusion medium was used. The perfusion rate in the recording
chamber was constantly kept at 1.0 ml/min. After placing the slices in the
submerged recording chamber field excitatory postsynaptic potentials
(fEPSPs) were recorded in stratum radiatum of CA1 region with a borosilicate
glass micropipette (resistance 3–15 MU) filled with 3 M NaCl at a depth of 90–
120 mm.Monopolar tungsten electrodeswere used for stimulating the Schaffer
collaterals at a frequency of 0.1 Hz. Stimulation was set to elicit a fEPSP with
a slope of 40% of maximum for LTP recordings and 60% for LTD recordings.
After 20 min prebaseline stimulation, the three different samples were washed
into the chamber and the baseline was recorded for another 40 min. LTP was
induced by applying theta-burst stimulation (TBS). One burst consists of four
pulses at 100 Hz, repeated 10 times in an 200 ms interval. Three such bursts
were used to induce LTP at 0.1 Hz.
To study the effect of NOS2 deficiency on LTP, brains were dissected and
sagittally sliced in 400 mm sections using a vibratome (Camden Instruments,
Integraslice 7550 PSDS). The recording of the field excitatory postsynaptic
potential (fEPSP) was initiated after 15 min of basal recording. Basal synaptic
transmission (BST) was assessed by plotting the current (mA) against the peak
amplitudes of fEPSP to generate input-output relations. Paired-pulse facilita-
tion (PPF) were recorded by applying interstimulus intervals of 30, 50, 75,
and 100 ms. For long-term potentiation (LTP) experiments a 15 min baseline
were recorded with a interpulse interval of 1 min at an intensity that evoked
a response approximately 30% of maximum fEPSP. The LTP was induced
by a theta burst consisting of 4 trains of 10 pulses at 100 Hz separated by
200 ms.
Data Analysis
Data were collected, stored and analyzed with LABVIEW software (National
Instruments, Austin, TX). The initial slope of fEPSPs elicited by stimulation
of the Schaffer collaterals was measured over time, normalized to baseline,
which was the mean response of the 40 min before TBS application and
plotted as average ± SEM. Parameters leading to an exclusion of single
experiments were (1) an unstable baseline (variability more than ± 10%) or
(2) a large population spike after TBS application producing an artificially
large LTP.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and Supplemental Experi-
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